This choice of an epigenetic-based therapeutic approach is motivated by a previous study that revealed a tumor cell autonomous drug resistance mechanism involving lapatinib-induced upregulation of receptor tyrosine kinases (RTKs) [39]. Here, NTRK1 is linked to neoplasm.